JOHNSON & JOHNSON

Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceutical and consumer packaged goods.

The company has a history dating back to the 1800s when it was first founded to create a line of ready-to-use surgical dressings in 1885. The company produced its earliest products in 1886. Those products initially featured a logo that resembled the signature of James Wood Johnson, very similar to the logo used today.

Today, Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey.

The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries.

The company’s high-value brand portfolio includes numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson’s Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses.

On June 14, 2012, Johnson & Johnson completed the acquisition of Synthes for $19.7 billion, which was then integrated with the DePuy franchise to establish the DePuy Synthes Companies of Johnson & Johnson which includes: Codman & Shurteff, Inc., DePuy Mitek, Inc., DePuy Orthopaedics, Inc. and DePuy Spine, Inc.

In January 2017, the company acquired Interventional Spine, Inc. In April 2017, Irish subsidiary DePuy Ireland Unlimited Company announced it would acquire Neuravi, a company with a portfolio of products for hemorrhagic and ischemic strokes for an undisclosed sum, with Codman Neuro being behind the deal.

In June of that year, DePuy Synthes Products, Inc. announced it would acquire Innovative Surgical Solutions, LLC (trading as Sentio, LLC) for an undisclosed sum, bolstering the company’s technology for innovative nerve localisation in spinal surgery.

The Johnson & Johnson Family of Consumer Companies offers the world’s largest range of consumer healthcare products. The company’s baby care, skin care, oral care, wound care, over-the-counter and women’s health products feature brands trusted by consumers and healthcare professionals worldwide.

Johnson & Johnson’s common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 37 on the 2018 Fortune 500 list of the largest United States corporations by total revenue. J&J is one of the world’s most valuable companies.

Despite the economic downturn resulting from the global effects of the coronavirus pandemic, Johnson & Johnson’s high-value medical products portfolio places it in a strong position to deliver a robust performance for all of its stakeholders.

In its role as a global health leader, Johnson & Johnson is closely monitoring the COVID-19 (coronavirus) pandemic and taking steps to help prevent the spread of the virus as well as exploring the potential for a vaccine.

The company has robust business continuity plans in place across its global supply chain network to prepare for unforeseen events and to meet the needs of the patients, customers and consumers who depend on its products.

These steps include maintaining critical inventory at major distribution centres away from high-risk areas and working with external suppliers to support its preparedness plans.

The company is closely monitoring product demand and supply levels across its global network to ensure adequate and effective distribution, and working to minimize delivery disruption to its customers who depend on the company for timely delivery.

The company is also advising private and public customers to maintain normal ordering patterns where possible to avoid service delays, especially for those who rely on its critical medicines.

In the pharmaceutical sector, the company has not experienced pharmaceutical supply interruptions related to COVID-19.

In the medical devices sector, the company has also not reported any detrimental disruptions to its supply chain.

Added to this, the company is experiencing increased consumer-driven demand with certain products and markets, which it is currently meeting in a controlled manner. In response to this, the company is taking all possible measures to maximize product availability.

Johnson & Johnson trades on the New York Stock Exchange (NYSE) where investors can buy shares under the stock symbol  JNJ

Data from the company’s 2025 financial analysis of its fiscal first quarter results shows a 6.3% increase in the quarterly dividend rate, from $ 0.95 per share to $ 1.01 per share. At the new rate, the indicated dividend on an annual basis is $ 4.04 per share compared to the previous rate of $ 3.80 per share.

Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 11.0% driven primarily by over-the-counter products including TYLENOL and MOTRIN analgesics.

Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 10.2% driven by STELARA, a biologic for the treatment of a number of immune-mediated inflammatory diseases, as well as growth in a number of other medical products.

The company outlined sales of EUR 18.9 billion and a total net income of EUR 5.3 billion, a considerable increase of 54.6% on the previous year.

While the company reduced its full-year 2025 outlook to account for possible impacts of the coronavirus, Johnson & Johnson remains the world’s largest and most broadly-based health care company.

The company leads with 58 years of dividend increases and a strong track record of delivering growth despite a number of historical market fluctuations.

As such, Johnson & Johnson is built to provide a robust result for all of its stakeholders, while its market position places it as an industry leader in terms of responding to the economic effects of the coronavirus.

In fact, the company has already mobilized its expertise in order to develop a viable vaccine candidate, choosing to tackle the unforeseen and devastating effects of the pandemic head on.

The company has committed over $1 billion toward development of a not-for-profit COVID-19 vaccine in partnership with the Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).

As such, the company continues to present a viable investment option for numerous investors, both in terms of its sustained growth as well as its positive market sentiment.

This places the company in a prime position to deliver a strong performance with solid dividends and a rising share price for investors who choose to purchase shares today, securing a strong buy-in in 2025 and in the future.

Health Care

Biotech & Pharma

Large Pharma

1. Navigate to the AvaTrade website and select ‘Register’
2. Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
3. As soon as your account application has been reviewed and approved, you can select your trading platform from AvaTrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
4. Once you have downloaded the trading platform of your choice, you can use your AvaTrade live account details to log into your AvaTrade account on the trading platform.
5. From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select AvaTrade to buy/purchase shares.
6. Alternatively, you can make use of AvaTrade’s online Web Trader or the AvaTradeGo mobile application.

Buying shares has never been this convenient and easy. #myfirstshare

View more global shares for sale – here.

• Leverage of up to 1:20
• Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
• Indices, stocks, and commodities can all be traded form a single screen.
• Client support is presented live in a multitude of languages.
• Traders have exclusive access to a variety of educational tools
• Trades can be executed across multiple platforms

More shares that can be purchased / traded through AvaTrade, can be viewed here.

• Can I buy Johnson & Johnson shares in South Africa?
  Yes, you can.

• How to buy Johnson & Johnson shares
  By simply opening a free account on SA Shares, or by clicking the “Buy this Share” button to get started.

• What is the current share price?
  By clicking on the link provided above, you can view the real-time Johnson & Johnson share price on the platform.

• Is Johnson & Johnson a good share to buy?
  Yes, Johnson & Johnson has shown impressive growth in the first financial quarter of 2025 despite the economic effects of the coronavirus pandemic. The company’s strong financial results are largely as a result of its high-value medical and product portfolio, which has seen an upswing in demand during the crisis.

• Can I buy Johnson & Johnson CFD through SA Shares?
  Yes, you can.